Llwytho...
Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus
BACKGROUND: It is unknown whether canagliflozin, a selective sodium glucose co-transporter 2 inhibitor, reduces epicardial adipose tissue (EAT) thickness, which is associated with insulin resistance and is a risk factor for coronary artery disease. METHODS AND RESULTS: We administered 100 mg of cana...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Diabetol Metab Syndr |
|---|---|
| Prif Awduron: | , , , , , , , , , , , , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
BioMed Central
2017
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5628447/ https://ncbi.nlm.nih.gov/pubmed/29034006 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13098-017-0275-4 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|